Novacyt
S.A.
("Novacyt", the "Company" or
the "Group")
Successful VAT reclaim of £12.2 million
Paris, France, and
Eastleigh and Manchester, UK - 22 August 2024 - Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM:
NCYT), an international molecular diagnostics company with a broad
portfolio of integrated technologies and services,
announces that it has
successfully reclaimed £12.2 million in VAT from HMRC, with the
full sum having been received by the Company.
As
announced in the AGM Statement issued on
18 July 2024, the Group submitted a request to reclaim
circa £12.2 million VAT relating to Department of Health and Social
Care ("DHSC") invoices that will now not be paid
following the dispute
settlement reached with the DHSC.
Following
settlement of the dispute, including the payment of £5.0 million to
the DHSC (paid in early July), the Group's net cash position has
increased by over £7.0 million.
This announcement
contains inside information for the purposes of Article 7 of
Regulation (EU) 596/2014.
Contacts
|
Novacyt SA
|
https://novacyt.com/investors
|
|
Lyn Rees, Chief Executive
Officer
|
Via Walbrook
PR
|
|
Steve Gibson, Chief Financial
Officer
|
|
|
SP
Angel Corporate Finance LLP (Nominated Adviser and
Broker)
|
+44 (0)20
3470 0470
|
|
Matthew Johnson / Charlie Bouverat
(Corporate Finance)
Vadim Alexandre / Rob Rees
(Corporate Broking)
|
|
|
|
|
|
Deutsche Numis (Joint
Broker)
|
+44 (0)20
7260 1000
|
|
Freddie Barnfield / Duncan Monteith
/ Michael Palser
|
|
|
|
|
|
Allegra Finance (French Listing Sponsor)
Rémi Durgetto / Yannick
Petit
|
+33 (1) 42 22 10 10
r.durgetto@allegrafinance.com
/ y.petit@allegrafinance.com
|
|
|
|
|
Walbrook PR
(Financial PR & IR)
Stephanie Cuthbert / Paul McManus
/
Phillip Marriage / Alice
Woodings
|
+44 (0)20
7933 8780 or novacyt@walbrookpr.com
+44
(0)7796 794 663 / +44 (0)7980 541 893
+44
(0)7867 984 082 / +44 (0)7407 804 654
|
|
|
|
|
| |
About Novacyt Group (www.novacyt.com)
Novacyt is an international
molecular diagnostics company providing a broad portfolio of
integrated technologies and services, primarily focused on the
delivery of genomic medicine. The
Company develops, manufactures, and
commercialises a range of molecular assays
and instrumentation to deliver workflows and services that enable
seamless end-to-end solutions from sample to result across multiple
sectors including human health, animal health and environmental.
The Company is divided into three
business segments:
|
Clinical
|
Broad portfolio of human clinical
in vitro diagnostic
products, workflows and services focused on three therapeutic
areas:
·
Reproductive Health: NIPT, Cystic Fibrosis and
other rapid aneuploidy tests
·
Precision Medicine: DPYD genotyping
assay
·
Infectious Diseases: Winterplex, multiplex winter
respiratory PCR panel
|
|
Instrumentation
|
Portfolio of next generation size
selection DNA sample preparation platforms and rapid
PCR machines, including:
·
Ranger® Technology: automated DNA sample
preparation and target enrichment technology
·
MyGo: real-time quantitative PCR (qPCR)
instruments
|
|
Research Use Only
|
Range of services for the life
sciences industry:
·
Design, manufacture, and supply of
high-performance qPCR assays and workflows for use in human health,
agriculture, veterinary and environmental, to support global health
organisations and the research industry
·
Pharmaceutical research services: whole genome
sequencing (WGS) / whole exome sequencing (WES)
|
Novacyt is headquartered in
Vélizy-Villacoublay in France with offices in the UK (in Stokesley,
Eastleigh and Manchester), Taipei, Singapore, the US and Canada and
has a commercial presence in over 65 countries. The Company is
listed on the London Stock Exchange's AIM market ("NCYT") and on
the Paris Stock Exchange Euronext Growth ("ALNOV").
For more information, please refer
to the website: www.novacyt.com